

Resource Summary Report

Generated by [nidm-terms](#) on Jul 28, 2026

OPKO

RRID:SCR_004035

Type: Tool

Proper Citation

OPKO (RRID:SCR_004035)

Resource Information

URL: <http://www.opko.com/>

Proper Citation: OPKO (RRID:SCR_004035)

Description: A multi-national pharmaceutical and diagnostics company that develops, manufactures, and distributes an extensive array of diagnostics and therapeutics for a wide range of indications and conditions. They focus on production of cardiovascular products, vaccines, hormones, antibiotics, gastrointestinal products, and eye care. The company operates in the U.S., Chile, Israel, Mexico, Uruguay, and Spain. (Adapted from Wikipedia)

Abbreviations: OPK

Synonyms: OPKO Health Inc., OPKO Health

Resource Type: commercial organization

Keywords: pharmaceutical, diagnostic, vaccine, cardiovascular, hormone, antibiotic, gastrointestinal, eye

Related Condition: Hyperparathyroidism, Vitamin D insufficiency, Asthma, Chronic obstructive pulmonary disease, Parkinson's disease, Chemotherapy-induced nausea and vomiting

Resource Name: OPKO

Resource ID: SCR_004035

Alternate IDs: nlx_158461, grid.497542.9, Wikidata: Q55454537

Alternate URLs: <https://ror.org/02kd16s45>

Record Creation Time: 20220129T080222+0000

Record Last Update: 20260725T190547+0000

Ratings and Alerts

No rating or validation information has been found for OPKO.

No alerts have been found for OPKO.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Horikawa R, et al. (2022) Efficacy and Safety of Once-Weekly Somatrogon Compared with Once-Daily Somatropin (Genotropin??) in Japanese Children with Pediatric Growth Hormone Deficiency: Results from a Randomized Phase 3 Study. *Hormone research in paediatrics*, 95(3), 275.

Wanowska E, et al. (2018) Natural antisense transcripts in diseases: From modes of action to targeted therapies. *Wiley interdisciplinary reviews. RNA*, 9(2).

Guzman-Aranguez A, et al. (2013) Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy. *British journal of pharmacology*, 170(4), 730.

Raemdonck K, et al. (2008) Maintaining the silence: reflections on long-term RNAi. *Drug discovery today*, 13(21-22), 917.